Ali Satvat

Ali Satvat (Menlo Park) joined KKR in 2012. He co-leads the Health Care industry team within KKR’s Americas Private Equity platform and serves as Global Head of KKR’s Health Care Strategic Growth platform. He is a member of the Investment Committee and the Portfolio Management Committee for Americas Private Equity and chairs the Investment Committee and the Portfolio Management Committee for Health Care Strategic Growth. Mr. Satvat has served on multiple public and private boards of directors, including most recently Blue Sprig Pediatrics, BridgeBio Pharma, Clarify Health Solutions, Cordis, Digital Diagnostics, Geode Health, Headlands Research, Impel NeuroPharma, Paige.AI, Sapphiros, SkinSpirit, Treeline Biosciences, and Trilogy MedWaste, and has been actively involved with various historical investments such as Ajax Health, Arbor Pharmaceuticals, Coherus BioSciences, Eidos Therapeutics, Falcon Vision, GenesisCare, Gland Pharma, Panasonic Healthcare, PRA Health Sciences, Slayback Pharma, Spirox and Zeus Health.

Prior to joining KKR, Mr. Satvat was a principal with Apax Partners, where he focused on health care private equity and growth equity investments. Previously, he held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. He previously served as a member of the board of directors of the Healthcare Private Equity Association.